business
JPMorgan Maintains an “Overweight rating” on Bruker Corporation (BRKR)
Key takeaways
- On June 8, JPMorgan analyst Casey Woodring raised the price target on Bruker Corporation (NASDAQ:BRKR) to $65 from $45.
- Days earlier, on June 4, Bruker Corporation (NASDAQ:BRKR) reported its growing microbiology and infection diagnostics portfolio at ASM Microbe 2026.
- The company said improvements to its MALDI Biotyper CA System include FDA-approved updates.
JPMorgan Maintains an “Overweight rating” on Bruker Corporation (BRKR) Fatima Gulzar Sat, June 27, 2026 at 10:31 PM GMT+7 1 min read BRKR BRKRP Bruker Corporation (NASDAQ:BRKR) is one of the 10 Best Brain-Computer Interface Stocks to Buy.
On June 8, JPMorgan analyst Casey Woodring raised the price target on Bruker Corporation (NASDAQ:BRKR) to $65 from $45. The firm maintained an "Overweight rating" on the share. It updated the company model.
Days earlier, on June 4, Bruker Corporation (NASDAQ:BRKR) reported its growing microbiology and infection diagnostics portfolio at ASM Microbe 2026. The firm detailed advances across microbial identification, sepsis diagnostics, molecular testing, and next-generation sequencing workflows.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Investing.com
S&P affirms U.S. sovereign rating at AA+, maintains stable outlook
Investing.com
JPMorgan reiterates Doximity stock Neutral rating with $26 target
Investing.com
Piper Sandler initiates Connect Biopharma stock with overweight rating
Investing.com
JPMorgan upgrades HB Fuller stock rating on EBITDA growth outlook
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop